Optiprost T Eye Drop contains Bimatoprost 0.3mg/ml + Timolol 5mg/ml, a dual-action anti-glaucoma ophthalmic formulation used for effective reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension. Its precise combination ensures enhanced pressure control with long-term safety.
The eye drop works by increasing aqueous humor outflow through Bimatoprost and reducing aqueous humor production via Timolol, delivering comprehensive intraocular pressure management and protecting optic nerve health.
From a franchise perspective, Optiprost T Eye Drop is a high-demand combination therapy, commonly prescribed in eye hospitals, specialty ophthalmology clinics, and glaucoma care centers, ensuring consistent prescriptions and repeat sales.
Adding Optiprost T Eye Drop to your portfolio strengthens the ophthalmic anti-glaucoma combination segment, offering long-term market stability, strong prescriber confidence, and enhanced portfolio value for PCD pharma franchise partners.